Insmed Delivers Rare Disappointment as Brinsupri Flops in Mid-Stage Rhinosinusitis Study

Insmed; Brensocatib; Brinsupri; DPP1 inhibitor; chronic rhinosinusitis without nasal polyps; mid-stage trial; Phase 2b; nasal inflammation; trial failure; biotech stocks; INS1148 acquisition

Nektar Digs Into Mid-Stage Data To Establish Alopecia Efficacy of Rezpeg

Nektar Therapeutics; rezpegaldesleukin; Rezpeg; REZOLVE-AA; Phase 2b; alopecia areata; hair loss; SALT score; mid-stage trial; efficacy signal; Eli Lilly; IL-2 pathway; autoimmune disease; Phase 3 planning